876 related articles for article (PubMed ID: 23949842)
1. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
Santos FN; de Castria TB; Cruz MR; Riera R
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
Santos FN; Castria TB; Cruz MR; Riera R
Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
8. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Luo J; Leaw SJ; Xu Y; Zheng D
Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Gao G; Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Lung Cancer; 2009 Sep; 65(3):339-44. PubMed ID: 19144444
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
17. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
[TBL] [Abstract][Full Text] [Related]
18. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
Ferry D; Billingham L; Jarrett H; Dunlop D; Woll PJ; Nicolson M; Shah R; Thompson J; Spicer J; Muthukumar D; Skailes G; Leonard P; Chetiyawardana AD; Wells P; Lewanski C; Crosse B; Hill M; Gaunt P; O'Byrne K
Eur J Cancer; 2017 Sep; 83():302-312. PubMed ID: 28780466
[TBL] [Abstract][Full Text] [Related]
20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
